Susceptibility of Human Prion Protein to Conversion by Chronic Wasting Disease Prions by A. Barria, Marcelo et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Susceptibility of Human Prion Protein to Conversion by Chronic
Wasting Disease Prions
Citation for published version:
A. Barria, M, Libori, A, Mitchell, G & Head, M 2018, 'Susceptibility of Human Prion Protein to Conversion by
Chronic Wasting Disease Prions', Emerging Infectious Diseases, pp. 1482-1489.
https://doi.org/10.3201/eid2408.161888
Digital Object Identifier (DOI):
10.3201/eid2408.161888
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Emerging Infectious Diseases
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Chronic wasting disease (CWD) is a contagious and fatal 
neurodegenerative disease and a serious animal health is-
sue for deer and elk in North America. The identification of 
the first cases of CWD among free-ranging reindeer and 
moose in Europe brings back into focus the unresolved is-
sue of whether CWD can be zoonotic like bovine spongi-
form encephalopathy. We used a cell-free seeded protein 
misfolding assay to determine whether CWD prions from 
elk, white-tailed deer, and reindeer in North America can 
convert the human prion protein to the disease-associated 
form. We found that prions can convert, but the efficiency of 
conversion is affected by polymorphic variation in the cervid 
and human prion protein genes. In view of the similarity of 
reindeer, elk, and white-tailed deer in North America to rein-
deer, red deer, and roe deer, respectively, in Europe, a more 
comprehensive and thorough assessment of the zoonotic 
potential of CWD might be warranted.
Chronic wasting disease (CWD) is a fatal contagious pri-on disease of cervids that is found in the United States, 
Canada, South Korea, and most recently in Europe (1,2). 
The species affected differ in these geographic areas; mule 
deer (Odocoileus hemionus), white-tailed deer (O. virginia-
nus), North American elk (Cervus canadensis), and moose 
(Alces alces) are most commonly affected in the United 
States and Canada, and red deer (C. elaphus) and sika deer 
(C. nippon) in South Korea also have been affected (1,2). 
The first identification of CWD in Europe occurred in 2016 
in wild moose (A. alces, also known as Eurasian elk) and in 
a free-ranging reindeer (Rangifer tarandus, closely related 
to the free-ranging caribou of North America), a species 
not previously known to be affected by CWD in wild or 
farmed animals (2,3). CWD is a pressing animal health is-
sue, but whether it might become a human public health 
issue should also be considered.
Scrapie and bovine spongiform encephalopathy (BSE) 
are well-characterized animal prion diseases affecting ani-
mals of consumption; scrapie affects sheep and BSE cattle. 
Human prion diseases occur as sporadic, genetic, and ac-
quired forms; the variant form of Creutzfeldt-Jakob disease 
is zoonotic BSE, acquired through the oral route and hav-
ing a long incubation period (4). In contrast, sheep scrapie 
is generally considered to be of no or only very low risk 
to human health, although this possibility has been ques-
tioned recently (5,6). The molecular basis of prion repli-
cation is a change in conformation of the normal cellular 
prion protein (PrPC) into the abnormal and misfolded con-
former (PrPSc) that is partially protease-resistant (PrPres). 
However, the molecular criteria for predicting zoonotic 
potential for prions are unclear. Consequently, approaches 
to understanding the zoonotic risk for prion transmission to 
humans have been empirical, involving in vivo and in vitro 
models (7). Experimental transmission of mule deer CWD 
to nonhuman primates showed that squirrel monkeys are 
susceptible, whereas cynomolgus macaques appear to be 
resistant (8,9). Similarly, attempted transmission of deer or 
elk CWD to transgenic mouse lines expressing human PrPC 
have largely failed, indicative of a species barrier (10–13), 
although this might be overcome in some instances (14).
In contrast to these in vivo approaches, we have used 
protein misfolding cyclic amplification (PMCA) to investi-
gate the molecular compatibility of bovine, ovine, and cervid 
prions with full-length, glycosylated and glycosylphospha-
tidylinositol-anchored human prion protein (PrP) (15,16). 
We found that scrapie samples failed to convert human PrPC 
to PrPres, whereas cattle BSE converted the human protein 
efficiently (15–17). These observations suggest that PMCA 
can reproduce aspects of cross-species transmission potential 
and inform assessment of zoonotic risk. The single CWD-
affected specimen (from a North American elk) previously 
available to us was found to be capable of converting hu-
man PrPC to PrPres (15). Here, we expand on the previous re-
port; analyzing more elk specimens of 2 different genotypes 
(132 MM, homozygous for methionine at Prnp position 132, 
and 132 ML, methionine–leucine heterozygous at the same 
position), analyzing white-tailed deer CWD specimens for 
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the first time, and analyzing reindeer that have been experi-
mentally infected with white-tailed deer CWD. The elk ML 
polymorphism at position 132 of Prnp is of particular inter-
est because it corresponds to the methionine–valine (MV) 
PRNP codon 129 polymorphism in humans, which is itself 
a major genetic susceptibility factor associated with human 
prion disease (18). Although these examples of CWD all 
derive from North America, the inclusion of white-tailed 
deer (a relative of European roe deer, Capreolus capreolus), 
North American elk (a near relative of red deer), and, most 
important, reindeer might help in formulating risk assess-
ments in Europe.
Materials and Methods
Animal Tissue
We obtained from the National and OIE Reference Labo-
ratory for Scrapie and CWD (Ottawa, ON, Canada) elk, 
white-tailed deer, and reindeer frozen brain tissue from 
CWD-affected animals that had been confirmed positive by 
using a statutory diagnostic testing regimen (Table). Small 
pieces of tissue were obtained, and we analyzed all for the 
presence of PrPres by using Western blot, as previously de-
scribed (15). We used transgenic mouse brains produced by 
gene replacement and expressing physiologic levels of the 
human PrP of the 3 PRNP codon 129 polymorphic geno-
types as the PMCA substrate (20).
Protein Misfolding Cyclic Amplification
Substrate and Seed Preparation
We homogenized transgenic mouse brains in conversion 
buffer by using a glass on glass manual grinder and a con-
version buffer made of 1× phosphate-buffered saline (PBS), 
150 mmol/L of NaCl, 1% Triton X-100, and a complete 
protease inhibitor cocktail (cOmplete; Roche, Mannheim, 
Germany) to obtain a final 10% weight-to-volume solution. 
We cleared the homogenized tissue by using centrifugation 
as described previously (15), aliquoted the supernatant (i.e., 
PMCA substrate) into 1.5 mL tubes, and stored at –80°C 
until used. We homogenized the CWD brain material (i.e., 
PMCA seed) by using 1.5-mL Eppendorf tubes and dispos-
able polypropylene pestles that used the same buffer.
PMCA Procedure
We performed amplification in a programmable Q-700 
sonicator attached to a microplate aluminum horn (15). We 
mixed brain homogenate CWD PMCA seeds with aliquots 
of PMCA substrate in a final volume of 120 µL in PCR 
tubes at a 1:3 ratio. We included low molecular weight hep-
arin at 100 µg/mL (21) in all PMCA reactions and added 
EDTA to a final concentration of 6 mmol/L. To perform a 
comparison between samples before and after the amplifi-
cation procedure, we took 19 µL of each reaction mixture 
before the serial cycles of sonication and incubation. Each 
cycle consisted of 20 s sonication (at an amplitude of 38, 
wattage 278–300) followed by 29 min and 40 s incubation; 
we repeated this procedure 96 times (48 h).
Proteolytic Treatment and Western Blotting
We evaluated the presence of PrPres by Western blot af-
ter proteinase K treatment. We incubated 19 µL of each 
sample with proteinase K in a final concentration of 50 
µg/mL for 1 h at 37°C in a standard thermoblock. Before 
loading, we mixed samples with an appropriate volume of 
4× NuPAGE buffer (Invitrogen, Carlsbad, CA, USA) and 
boiled them at 100°C for 10 min. We loaded the samples 
on NuPAGE Novex (Fisher Scientific; Loughborough, 
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Table. Description of cervid CWD specimens used to evaluate the susceptibility of human prion protein to conversion by in vitro 
conversion analysis* 
Species  
Common name Specimen 
ID 
Disease in captive animals or 
experimental transmission 
Prnp genotype, known 
relevant polymorphisms North America Europe 
Cervus canadensis North American or 
Rocky Mountain 
elk or wapiti 
Closely related 
to red deer 
(Cervus elaphus) 
Elk 0† Captive 132 MM 
Elk 1 Captive 132 MM 
Elk 2 Captive 132 MM 
Elk 3 Captive 132 MM 
Elk 4 Captive 132 MM 
Elk 5 Captive 132 ML 
Elk 6 Captive 132 ML 
Odocoileus 
virginianus 
White-tailed deer Related to roe 
deer (Capreolus 
capreolus) 
WTD 1 Experimental 96 GG 
WTD 2 Experimental 96 GG 
Rangifer tarandus 
subspecies 
Caribou (free-
ranging) or 
reindeer (captive) 
Reindeer (free-
ranging and 
captive) 
Reindeer 1 Experimental (transmission of 
WTD [CWD 96GG])‡ 
§ 
Reindeer 2 Experimental [transmission of 
WTD (CWD 96GG)]¶ 
§ 
*CWD, chronic wasting disease; WTD, white-tailed deer. 
†Previously reported in Barria et al. (15). 
‡Case 12 previously reported in Mitchell et al. (19). 
§Reportedly identical to the case of CWD in a wild reindeer in Norway (Benestad et al. [2]). 
¶Case 47 previously reported in Mitchell et al. (19). 
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United Kingdom) 10% Bis-Tris gels (1.0 mm, 10 wells) 
and subjected them to electrophoresis at 200 volts for 55 
min. We transferred proteins to a polyvinylidene difluoride 
membrane by using 800 mA for 60 min (15) and blocked 
membranes with 2% milk for 1 h. We determined accu-
mulated human PrPres on the basis of the specific immuno-
reactivity of the 3F4 monoclonal antibody (mAb) diluted 
1/10,000 (Millipore; Watford, United Kingdom). We de-
tected CWD PrP by stripping the Western blots (Thermo 
Fisher, Bleiswijk, Netherlands) and reprobing them with a 
6H4 antibody diluted 1/40,000 (Prionics; Schlieren, Swit-
zerland). We used ECL antimouse IgG, peroxide-linked 
species-specific F(ab′)2 fragment from sheep (GE Health-
care Life Sciences; Little Chalfont, United Kingdom) as a 
secondary antibody diluted 1/25,000. We developed mem-
branes by chemiluminescent detection using ECL Prime 
(GE Healthcare Life Sciences) and acquired digital images 
by using an XRS Bio-Rad system (Bio-Rad Laboratories, 
Hercules, CA, USA) with a CCD camera.
Criteria for Positivity
The criterion for conversion was 3F4 antibody detection of 
a pattern of 3 clear protease-resistant bands of the expected 
electrophoretic mobility and ratio for PrPres in the amplified 
sample after a defined period of Western blot image capture. 
The triplet pattern had to be absent from the unamplified 
sample tested under the same conditions analyzed in parallel.
Precipitation of Insoluble PrP
We incubated brain homogenate from white-tailed deer and 
reindeer CWD specimens by using 20% sarkosyl (diluted 
in PBS) for 10 min at room temperature. We subjected sam-
ples to centrifugation for 1 h at 100,000 × g at 4°C as de-
scribed previously (21). After centrifugation, we discarded 
the supernatant and washed the pellet with PBS followed 
by a second centrifugation (100,000 × g for 1 h at 4°C). We 
resuspended the washed pellets directly in PMCA substrate 
before using them in a single round of amplification.
Results
Determination of Total PrP in Cervid CWD Specimens
We first characterized the CWD brain tissues for the pres-
ence of total PrP and PrPres by using mAb 6H4. We detected 
similar levels of total PrP by using Western blotting among 
the elk specimens analyzed (Figure 1). However, we did 
not find readily detectable levels of PrPres in all the samples; 
we detected PrPres in 3 of the 5 elk specimens of the 132 
MM genotype and both of the 132 ML samples (Figure 2, 
panels A and C). White-tailed deer samples showed similar 
expression levels of total PrP in the 2 specimens analyzed, 
but PrPres levels were low (Figures 1,3). We also confirmed 
total PrP in the reindeer specimens, with a robust detection 
of PrPres in 1 of the available samples (reindeer 1) but low 
levels in the other specimen (reindeer 2) (Figures 1,4).
In vitro Conversion of Human PrP by Cervid Prions
Elk (C. Canadensis)
We then performed a single round of PMCA, incubating 
the PRNP codon 132 MM elk CWD seeds in humanized 
transgenic 129 MM mouse brain substrate. Only those elk 
CWD samples that had readily detectable PrPres (as detect-
ed by 6H4 mAb) were able to produce human PrPres (detect-
able by the 3F4 mAb) after Western blot and proteinase K 
treatment, consistent with CWD PrPres playing a direct role 
in the misfolding process (Figure 2, panel A).
We then addressed the role of the human PRNP codon 
129 and the cervid PRNP codon 132 polymorphisms in the 
conversion of human PrPC. To seed PMCA reactions, we 
1484 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 8, August 2018
Figure 1. Western blot analysis showing detectable levels of prion protein in the chronic wasting disease–affected cervid brain 
specimens used to evaluate the susceptibility of the human prion protein (PrP) to conversion by chronic wasting disease prions. We 
analyzed brain homogenate derived from elk, white-tailed deer, and reindeer specimens by using Western blot to evaluate levels of total 
PrP. We subjected 2 µL of each 10% brain homogenate sample to Western blot and assessed detection of total PrP by mAb 6H4. We 
performed 3 technical repeats with similar results; a representative Western blot is shown. Reference molecular markers have been 
included. mAb, monoclonal antibody.
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used CWD brain homogenates from 132 MM and 132 ML 
elk with comparable quantities of CWD PrPres (Figure 2, 
panel C) and then used humanized transgenic mouse sub-
strates of the 3 possible PRNP codon 129 genotypes (129 
MM, 129 MV, and 129VV). Each of the CWD methionine 
homozygous (132 MM) samples resulted in human PrPres 
formation when used to seed the matched humanized sub-
strate (129 MM). The heterozygous elk seeds did not result 
in any detectable conversion of the humanized 129 MM 
PrP substrate. When we incubated these same CWD brain 
homogenates with the heterozygous (129 MV) and homo-
zygous (129VV) humanized substrates, we observed low 
levels of human PrPres formation but no obvious difference 
in efficiency between the CWD 132MM and CWD 132ML 
samples in the 129VV substrate (Figure 2, panel B).
White-tailed Deer (O. virginianus)
We performed similar analyses to determine the com-
petence of white-tailed deer CWD to convert the human 
PrP (Figure 3). To maintain consistency, we homogenized 
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Figure 2. Evaluation of the in vitro conversion of human prion protein (PrP) seeded with the misfolded, disease-associated prion protein 
form present in chronic wasting disease (CWD)–affected elk brain samples. Western blot analysis for PrP with odd and even number 
lanes showing reaction mixtures before and after protein misfolding cyclic amplification. A) We incubated 5 elk CWD specimens (elk 
0–4) homozygous for Prnp codon 132 methionine (MM) in Tg-HuMM brain substrate (diluted 1:3) and subjected them to a single round 
of protein misfolding cyclic amplification followed by proteinase K digestion. We performed Western blot analysis by using the mAb 
3F4 (for the detection of human protease-resistant prion protein [PrPres]) and 6H4 (detection of CWD PrPres and human PrPres). B) We 
used a panel of 3 humanized transgenic substrates (Tg-HuMM, Tg-Hu-MV, and Tg-HuVV) to evaluate the susceptibility of the human 
PrP to conversion. We assessed 3 CWD elk seeds of the132 MM genotype and 2 of the 132 methionine–leucine (ML) genotype. We 
detected conversion of the human PrP by CWD prions by using the mAb 3F4 after proteinase K digestion. C) We detected total PrPres 
by using Western blot with mAb 6H4. The elk specimen previously reported (15) is designated elk 0. We performed >5 repeats for the 
amplification of elk CWD 132 MM seeds and >3 for the 132 ML specimens with similar results. Reference molecular markers have been 
included. Molecular mass of electrophoretic markers is given. mAb, monoclonal antibody; Tg-HuMM, humanized transgenic PRNP 
codon 129 homozygous methionine; Tg-HuMV, humanized transgenic methionine/valine; Tg-HuVV, humanized transgenic valine/valine. 
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the 2 available CWD white-tailed deer specimens at 10% 
(weight/volume) and then normalized by volume (seed/
substrate) to seed the PMCA reactions. Detection of CWD 
PrPres by 6H4 antibody revealed that the levels of PrPres 
in the unamplified samples were not equivalent to the 
elk CWD specimens used for PMCA (Figure 2, panel C; 
Figure 3). However, 1 of the analyzed specimens showed 
some conversion of the humanized 129 MM PrP substrate, 
although PrPres formation was undetectable in the hetero-
zygous and valine homozygous substrate with the 3F4 an-
tibody (Figure 3). These results suggest a higher degree of 
molecular compatibility of the PRNP codon 129 MM hu-
man genotype and CWD PrPSc, consistent with what we 
observed in most of the elk CWD 132 MM specimens.
Reindeer (R. tarandus)
Natural cases of CWD in reindeer have been detected in 
Norway, but North American reindeer were previously 
shown to be experimentally susceptible to white-tailed deer 
CWD by the oral route (18). We tested samples from these 
2 experimentally infected reindeer (18) (Figure 4). Both 
reindeer specimens were capable of converting the human-
ized 129 MM PrP substrate, although different amounts 
of CWD PrPres were detected by the 6H4 antibody in the 
frozen samples. Densitometry analysis suggested that 1 
specimen (from reindeer 2) had roughly one tenth of the 
PrPres of the other sample, showing that the reaction with 
small amounts of reindeer PrPres are able to convert the 
humanized substrate. The PRNP codon 129 MV and VV 
genotype substrates also were readily susceptible to conver-
sion by the reindeer seeds (Figure 4). Seeding efficiency of 
reindeer CWD was maintained when the seeding material 
was normalized by using semipurified PrPres (Figure 5), argu-
ing against the possibility that the apparent enhanced seed-
ing potential of reindeer CWD simply reflects the increased 
abundance of PrPres in reindeer samples or was a result of 
conversion of endogenous reindeer seed–associated PrPC.
Discussion
Characterization of the transmission properties of CWD 
and evaluation of their zoonotic potential are important 
for public health purposes. Given that CWD affects sev-
eral members of the family Cervidae, it seems reasonable 
to consider whether the zoonotic potential of CWD prions 
could be affected by factors such as CWD strain, cervid 
species, geographic location, and Prnp–PRNP polymor-
phic variation. We have previously used an in vitro con-
version assay (PMCA) to investigate the susceptibility 
of the human PrP to conversion to its disease-associated 
form by several animal prion diseases, including CWD 
(15,16,22). The sensitivity of our molecular model for 
the detection of zoonotic conversion depends on the com-
bination of 1) the action of proteinase K to degrade the 
abundant human PrPC that constitutes the substrate while 
only N-terminally truncating any human PrPres produced 
and 2) the presence of the 3F4 epitope on human but not 
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Figure 3. Evaluation of the in vitro 
conversion of human prion protein 
(PrP) seeded with the misfolded, 
disease-associated prion protein 
form present in chronic wasting 
disease (CWD)–affected white-
tailed deer brain samples. We 
incubated 2 white-tailed deer CWD 
brain homogenates, derived from 2 
affected animals (white-tailed deer 
1 and 2), in a panel of 3 humanized 
transgenic substrates (Tg-HuMM, 
Tg-HuMV, and Tg-HuVV) and 
subjected them to a single round 
of protein misfolding cyclic 
amplification (PMCA) followed by 
proteinase K digestion. We diluted 
CWD brain homogenate 1:3 in 
PMCA substrate and performed 
Western blot analysis by using 
the mAb 3F4 (for the detection of 
human protease-resistant prion 
protein [PrPres]) and mAb 6H4 
(for detection of CWD PrPres and 
human PrPres). We incorporated the 
elk specimen designated elk 0 as a control. We performed >3 repeats for the amplification of white-tailed deer CWD 1 and 2 specimens 
with similar results. Reference molecular markers have been included. Molecular mass of electrophoretic markers is given. Odd and 
even number lanes show reaction mixtures before and after PMCA. mAb, monoclonal antibody; Tg-HuMM, humanized transgenic PRNP 
codon 129 homozygous methionine; Tg-Hu-MV, humanized transgenic methionine/valine; Tg-HuVV, humanized transgenic valine/valine. 
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cervid PrP. In effect, this degree of sensitivity means that 
any human PrPres formed during the PMCA reaction can 
be detected down to the limit of Western blot sensitiv-
ity. In contrast, if other antibodies that detect both cervid 
and human PrP are used, such as 6H4, then newly formed 
human PrPres must be detected as a measurable increase in 
PrPres over the amount remaining in the reaction product 
from the cervid seed. Although best known for the efficient 
amplification of prions in research and diagnostic contexts, 
the variation of the PMCA method employed in our study 
is optimized for the definitive detection of zoonotic reac-
tion products of inherently inefficient conversion reactions 
conducted across species barriers. By using this system, we 
previously made and reported the novel observation that elk 
CWD prions could convert human PrPC from human brain 
and could also convert recombinant human PrPC expressed 
in transgenic mice and eukaryotic cell cultures (15).
A previous publication suggested that mule deer PrPSc 
was unable to convert humanized transgenic substrate in 
PMCA assays (23) and required a further step of in vitro 
conditioning in deer substrate PMCA before it was able 
to cross the deer–human molecular barrier (24). However, 
prions from other species, such as elk (15) and reindeer af-
fected by CWD, appear to be compatible with the human 
protein in a single round of amplification (as shown in our 
study). These observations suggest that different deer spe-
cies affected by CWD could present differing degrees of 
molecular compatibility with normal form of human PrP.
The contribution of the polymorphism at codon 129 
of the human PrP gene has been extensively studied and 
is recognized as a risk factor for Creutzfeldt-Jakob disease 
(4). In cervids, the equivalent codon corresponds to the po-
sition 132 encoding methionine or leucine. This polymor-
phism in the elk gene has been shown to play an important 
role in CWD susceptibility (25,26). We have investigated 
the effect of this cervid Prnp polymorphism on the conver-
sion of the humanized transgenic substrate according to the 
variation in the equivalent PRNP codon 129 polymorphism. 
Interestingly, only the homologs methionine homozygous 
seed–substrate reactions could readily convert the human 
PrP, whereas the heterozygous elk PrPSc was unable to do 
so, even though comparable amounts of PrPres were used to 
seed the reaction. In addition, we observed only low levels 
of human PrPres formation in the reactions seeded with the 
homozygous methionine (132 MM) and the heterozygous 
(132 ML) seeds incubated with the other 2 human polymor-
phic substrates (129 MV and 129 VV). The presence of the 
amino acid leucine at position 132 of the elk Prnp gene has 
been attributed to a lower degree of prion conversion com-
pared with methionine on the basis of experiments in mice 
made transgenic for these polymorphic variants (26). Con-
sidering the differences observed for the amplification of the 
homozygous human methionine substrate by the 2 polymor-
phic elk seeds (MM and ML), reappraisal of the susceptibil-
ity of human PrPC by the full range of cervid polymorphic 
variants affected by CWD in would be warranted.
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Figure 4. Evaluation of the in 
vitro conversion of human prion 
protein (PrP) seeded with the 
misfolded, disease-associated 
prion protein form present in 
chronic wasting disease (CWD)–
affected reindeer brain samples. 
We incubated 2 reindeer CWD 
specimens (reindeer 1 and 2) in a 
panel of 3 humanized transgenic 
substrates (Tg-HuMM, Tg-HuMV, 
and Tg-HuVV) and subjected 
them to a single round of protein 
misfolding cyclic amplification 
(PMCA). We diluted PMCA seeds 
3 times in fresh PMCA substrate 
(dilution factor 1:3) and evaluated 
PMCA reactions for the presence 
of protease-resistant prion protein 
(PrPres) by proteinase K digestion. 
We performed Western blot 
analysis by using mAb 3F4 (for 
the detection of human PrPres) 
and mAb 6H4 (for detection 
of CWD PrPres and human PrPres). We incorporated the elk specimen designated elk 0 as a control. We performed >5 repeats for the 
amplification of reindeer 1 and 2 specimens. Reference molecular markers have been included. Molecular mass of electrophoretic 
markers is given. Odd and even number lanes show reaction mixtures before and after PMCA. mAb, monoclonal antibody; Tg-HuMM, 
humanized transgenic PRNP codon 129 homozygous methionine; Tg-Hu-MV, humanized transgenic methionine/valine; Tg-HuVV, 
humanized transgenic valine/valine. 
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In light of the recent identification of the first cases of 
CWD in Europe in a free-ranging reindeer (R. tarandus) 
in Norway (2), we also decided to evaluate the in vitro 
conversion potential of CWD in 2 experimentally infected 
reindeer (18). Formation of human PrPres was readily 
detectable after a single round of PMCA, and in all 3 hu-
manized polymorphic substrates (MM, MV, and VV). This 
finding suggests that CWD prions from reindeer could be 
more compatible with human PrPC generally and might 
therefore present a greater risk for zoonosis than, for exam-
ple, CWD prions from white-tailed deer. A more compre-
hensive comparison of CWD in the affected species, cou-
pled with the polymorphic variations in the human and deer 
PRNP–Prnp genes, in vivo and in vitro, will be required 
before firm conclusions can be drawn. Analysis of the Prnp 
sequence of the CWD reindeer in Norway was reported to 
be identical to the specimens used in our study (2). This 
finding raises the possibility of a direct comparison of zoo-
notic potential between CWD acquired in the wild and that 
produced in a controlled laboratory setting. (Table).
The prion hypothesis proposes that direct molecular 
interaction between PrPSc and PrPC is necessary 
for conversion and prion replication. Accordingly, 
polymorphic variants of the PrP of host and agent might 
play a role in determining compatibility and potential 
zoonotic risk. In this study, we have examined the 
capacity of the human PrPC to support in vitro conversion 
by elk, white-tailed deer, and reindeer CWD PrPSc. Our 
data confirm that elk CWD prions can convert the human 
PrPC, at least in vitro, and show that the homologous 
PRNP polymorphisms at codon 129 and 132 in humans 
and cervids affect conversion efficiency. Other species 
affected by CWD, particularly caribou or reindeer, also 
seem able to convert the human PrP. It will be important 
to determine whether other polymorphic variants found 
in other CWD-affected Cervidae or perhaps other factors 
(17) exert similar effects on the ability to convert human 
PrP and thus affect their zoonotic potential.
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Figure 5. Schematic representation of the partial purification of 
misfolded, disease-associated prion protein from chronic wasting 
disease (CWD)–affected deer brain specimens and its continued 
ability to seed the conversion of human prion protein (PrP) during 
protein misfolding cyclic amplification (PMCA) reactions. We 
normalized PrP, partially purified by detergent insolubility from 
reindeer and white-tailed deer CWD specimens, by using protease-
resistant prion protein (PrPres) and subjected PrP to a single round 
of PMCA in humanized transgenic PRNP codon 129 homozygous 
methionine. We performed Western blot analysis by using mAb 3F4 
(for detection of human PrPres) and mAb 6H4 (for detection of CWD 
PrPres and human PrPres). Molecular mass of electrophoretic markers 
is given. Odd and even number lanes show reaction mixtures 
before and after PMCA. mAb, monoclonal antibody; PMCA, protein 
misfolding cyclic amplification; PrPC, normal isoform of the prion 
protein; PrPSc, disease-associated isoform of the prion protein. 
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